Clinical trial
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
NCT00263783 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00263783 |
|---|---|
| Title | Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors |
| Official title | Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | MEDI-522 |
| Enrollment | 24 |
| Start date | Mar 1, 2001 |
| Primary completion | Apr 1, 2002 |
| Completion | Jun 1, 2002 |
| First posted | Dec 9, 2005 |
| Last update posted | Jan 29, 2009 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: